Pharmaceutical Executive
WEBBy Don Tracy, Associate Editor. September 20th 2024. Rybrevant is the first targeted second-line regimen to significantly reduce the risk of disease progression by more than 50% in patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer, according to Johnson & Johnson. Bringing Marketing to a New Audience: Q&A …
2024 Pharm Exec Top 50 Companies
WEBJun 14, 2024 · Dethroning Pfizer at the top of our Pharma 50 is Johnson & Johnson ($53.46 billion in Rx sales), up 6.5% and jumping from third, driven by its “fairly diversified portfolio,” notes Verdin. J&J boasts a pair of treatments among the industry’s top-10 sellers (see chart above), including its longtime immunosuppressant, Stelara, which went ...
2022 Pharm Exec Top 50 Companies
WEBJun 9, 2022 · If 2020 was the “Year of COVID,” as we referred to it in our Pharm Exec 50 feature last year—reflecting on the pandemic’s scope and disruption on all facets of life—then 2021 was surely the year of COVID vaccines and treatments. And, through the prism of our latest rankings of the top 50 global biopharma players based on prescription …
2021 Pharm Exec Top 50 Companies
WEBJun 9, 2021 · Manning the last two positions in the Pharma 50 top 10 are once again GlaxoSmithKline and Takeda. GSK, still planning to split the organization into two next year, recently announced plans to sell its complete stake in respiratory drug partner Innoviva (a royalty management company) for about $392 million.
Pharm Exec's Top 50 Companies 2020
WEBJul 9, 2020 · Together, BMS and Celgene spent an estimated $9.4 billion in R&D last year, ranking second in this metric, with Johnson & Johnson and Merck manning third and fourth, respectively. Earlier this year, Brand Finance, the independent branded business valuation consultancy, named J&J its 2020 most valuable pharma company, due to J&J’s strong …
Pharm Exec 50: The World's Top 50 Pharmaceutical Companies
WEBMay 1, 2006. Article. Pharmaceutical Executive. Pharmaceutical Executive Pharmaceutical Executive-05-01-2006. Volume 0. Issue 0. Changing Landscapes: A Special Report on the World?s Top 50 Pharma Companies. External Link - …
China 2021: The NRDL Readout - PharmExec
WEBJan 4, 2022 · The 2021 NRDL signals ongoing emphasis on innovations. Of the 74 new NRDL inclusions, 26 were newly approved in 2021, and 20 were approved in 2020. Together they amount to 62 percent of the new inclusions total. For oncology new additions as an example, innovative therapies made the list with record speed, as the average …
China’s 2022 NRDL Outlook - PharmExec
WEBOct 3, 2022 · China’s 2022 NRDL Outlook. The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent. The first round of the 2022 National Reimbursement Drug List (NRDL) review took …
All News - PharmExec
WEBFDA Approves Ebglyss for Moderate-to-Severe Atopic Dermatitis. Don Tracy, Associate Editor. September 16th 2024. Results from the ADvocate 1, ADvocate 2, and ADhere clinical trials found that patients treated with Ebglyss 38% of patients with moderate-to-severe atopic dermatitis achieved clear or almost-clear skin after 16 weeks of treatment.
Pharmaceutical Executive's 2022 Emerging Pharma Leaders
WEBMay 11, 2022 · Click on the links below to read the profiles of Pharm Exec's 2022 Emerging Pharma Leaders.. Naveen Bazaj, Head of Corporate Development, Alector. Gardner Gendron, Chief/US Head of Commercial, NS Pharma. Aida Habtezion, MD, Senior VP, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer. Matthew J. …
- Some results have been removed